Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer

PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging. The objective of this study was to determine whether the combination...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Lin, Z. Ping, Zhu, Yong-Lian, Lo, Ying-Chun, Moscarelli, Jake, Xiong, Amy, Korayem, Yasmin, Huang, Pamela H., Giri, Smith, LoRusso, Patricia, Ratner, Elena S.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239325/
https://ncbi.nlm.nih.gov/pubmed/30444904
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0207399
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars